Mr. Sebastien Plouffe reports

DEFENCE ARRANGES FINANCING

Defence Therapeutics Inc. has arranged a non-brokered private placement of up to $4.2-million at 60 cents per unit comprising up to seven million units of the company.

Each unit comprised one common share in the capital of the company and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one additional common share at a price of 75 cents per common share for a period of 24 months of the closing date.

The company intends to use the net proceeds to advance its preclinical and clinical programs, and for general working capital. The company may pay a finder's fee in connection with the offering in accordance with the policies of the Canadian Securities Exchange. The securities issued in connection with the offering will be subject to a statutory hold period of four months and one day following the closing date in accordance with the CSE.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

We seek Safe Harbor.